Excellent
Aligned
Patient Risk:
Low
Summary
The claim exactly matches the boxed warning guidance to consider an alternative platelet P2Y12 inhibitor in CYP2C19 poor metabolizers due to diminished clopidogrel antiplatelet activity.
Category Scores
Accurate Statements
Use/Consider an alternative platelet P2Y12 inhibitor in patients who are CYP2C19 poor metabolizers to address diminished clopidogrel antiplatelet activity.
BOXED WARNING: states clopidogrel has reduced antiplatelet effect in patients homozygous for nonfunctional CYP2C19 alleles (CYP2C19 poor metabolizers) and: "Consider use of another platelet P2Y12 inhibitor" in these patients. Also supported by Section 5.1 (impaired CYP2C19 function/genetic variations) and Section 12.5 (diminished active metabolite exposure and platelet aggregation inhibition in poor metabolizers).
Unsupported Statements
Contradictions
Important Omissions
Safety Assessment
Potential Patient Risk:
Low
The recommendation is directly stated in the boxed warning for CYP2C19 poor metabolizers.
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Aligned
Primary Issue
Suggested Improvement